Innovation Medicine multipoint flowering kunyao group announces the development progress of dihydroartemisinin

The second phase of the clinical trial is planned to be carried out in 15 hospitals, and has now been carried out in 6 hospitals including Beijing Union Medical College Hospital, kunyao group said Tuesday< br / > dihydroartemisinin tablets for the treatment of lupus erythematosus has entered the second phase of clinical < br / > October 2015Tu youyou became the first Chinese native scientist to win the Nobel Prize for science because of the discovery that artemisinin can effectively reduce the mortality of malaria patients< br / > Kunming Pharmaceutical Group has been involved in the R & D and production of artemisinin antimalarial drugs for more than 50 yearsSince taking part in artemisinin project development in 1960s, kunyao has been responsible for artemisinin extraction and industrializationAt present, Kunming Pharmaceutical Co., Ltdnot only has a complete industrial chain of artemisinin business, but also is the world's largest manufacturer of raw materials for antimalarial drugs and the world's most comprehensive supplier of antimalarial drugsAt present, artemisinin products are mainly sold: compound naphthoquine phosphate tablets, artemether tablets, artemether raw materials, artemether injection, dihydroartemisinin piperaquine tablets< br / > in September 2016, Kunming Pharmaceutical Group announced to sign the transfer contract of new indications of dihydroartemisinin tablets - lupus erythematosus project with Institute of traditional Chinese medicine, Chinese Academy of traditional Chinese medicine, Purchase the relevant patents and clinical approvals obtained by the preclinical research institute of the new indication of dihydroartemisinin tablets lupus erythematosus research and development project developed by Professor Tu youyou from the Institute of traditional Chinese medicine, Chinese Academy of Sciences< br / > as a partner, Kunming Pharmaceutical Group is responsible for carrying out clinical trials on the "clinical trials of indications of dihydroartemisinin tablets in the treatment of systemic lupus erythematosus and discoid systemic lupus erythematosus" submitted and approved by the Institute of traditional Chinese medicine of the Chinese Academy of Chinese medicine where Tu youyou's team is located< br / > according to Kunming Pharmaceutical Group, the project is in the second phase of clinical trials, and is ready to do clinical trials in 15 hospitals, and has been carried out in 6 hospitals including Beijing Union Medical College Hospital< br / > in addition, the announcement issued by Kunming Pharmaceutical Group on the evening of the 17th said that the follow-up phase III clinical trial and the registration and approval procedures of the drug administration are also requiredOnly after the results of phase II and phase III clinical trials show the effectiveness and safety of dihydroartemisinin tablets in the treatment of lupus erythematosus, can the company submit a new drug registration application to the drug administrationIt is reported that kunyao group was founded in 1951 and listed on the Shanghai Stock Exchange in December 2000As an old pharmaceutical enterprise, Kunming Pharmaceutical Group has profound professional pharmaceutical experience, and is a national key high-tech enterprise and one of the top 100 pharmaceutical enterprises in China< br / > in recent years, in addition to continuing to grow and strengthen botanical medicine, traditional Chinese medicine and chemical medicine, Kunming Pharmaceutical Group has also increased its capital investment, accelerated its entry into the new drug development stage of complete innovation based on natural medicine through technological innovation, and has developed class 1 innovative drugs, such as panak, Arco, etc< br / > since 2018, Kunming Pharmaceutical Group has adjusted the layout of R & D resources and set up R & D institutions in Shanghai, Kunming and Beijing Shanghai has set up three R & D platforms, namely small molecule innovative drugs, large molecule biological drugs and high-end generic drugs, to boost the pace of transformation of enterprises; Kunming R & D center relies on the company's production base, focusing on the pilot test and industrialization of new product R & D in the later stage and the secondary development of listed products; Beijing R & D business department relies on the advantages of government resource concentration, Mainly responsible for the application of drug R & D registration documents < br / > at the same time, six innovation teams led by top experts at home and abroad, including the scientific and technological innovation team of the research on the pharmacobiology of stroke treatment, the innovation team of the diabegone project, the innovation team of the biological research and evaluation, the innovation team of the drug structure transformation, the innovation team of the research and development of new preparations, and the research and development innovation team of artemether series products in Yunnan Province, have been established successively < br / > in the key research and development projects of its layout, in addition to dihydroartemisinin tablets for the treatment of lupus erythematosus entering the clinical phase II trial, the biological products of class 1 new drug, long-acting hypoglycemic drug, supaluptide injection and the natural drug for the treatment of stroke of class 1 new drug, kpcxm18 for injection, obtained the clinical approval < br / > in addition, in order to further enhance the secondary development of artemisinin products, Kunming Pharmaceutical Group has increased the research and development of artemisinin derivative artemether in leukemia, lung cancer, colorectal cancer, glioma and other aspects, and has obtained 9 invention patents, including "a drug composition for lung cancer treatment" < br / > at present, Kunming Pharmaceutical Group is focusing on the treatment fields of cardiovascular and cerebrovascular diseases, neurology, autoimmune diseases, etc., and taking technological innovation as the lead, accelerating the transformation of the company to an innovative enterprise.